Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Aim: We report an exploratory analysis of cfRNA as a biomarker to monitor clinical responses in non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer (CRC). An analysis of cfRNA as a method for measuring PD-L1 expression with comparison to clinical responses was also performed in...

Descripción completa

Detalles Bibliográficos
Autores principales: Raez, Luis E., Danenberg, Kathleen, Sumarriva, Daniel, Usher, Joshua, Sands, Jacob, Castrellon, Aurelio, Ferraro, Pablo, Milillo, Adriana, Huang, Eric, Soon-Shiong, Patrick, Reddy, Sandeep, Danenberg, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992448/
https://www.ncbi.nlm.nih.gov/pubmed/35582387
http://dx.doi.org/10.20517/cdr.2021.78

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992448/
https://www.ncbi.nlm.nih.gov/pubmed/35582387
http://dx.doi.org/10.20517/cdr.2021.78

Ejemplares similares